Activa® Therapy increases "on" time by over 6 hours

In a multicentre clinical trial in which the Activa system was implanted, stimulating the STN in patients with idiopathic Parkinson's disease, the duration of 'On' time was increased by an average of 6.1 hours per day, 12 months post-implant ¹*.

Activa therapy significantly reduces the need for anti-parkinsonian medication
Levodopa-induced dyskinesias are reduced by 2.9 hours per day on average following STN stimulation ², possibly associated with a reduction in medication ^3-4.

Studies have shown that stimulation of the STN allows significant reduction in the levodopa equivalent daily dose (LEDD) ^5-6, with levodopa being completely withdrawn in some patients ^7,8,9.

Levodopa-induced dyskinesia at baseline and at 12 months (n=40) 3	Reduction in levodopa-equivalent daily dose (LEDD) and improvement in dyskinesias following stimulation of the STN

References:

2. Benabid AL, Pollak P, Louveau A et al. Combined thalamotomy and stimulation stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson's disease. Appl Neurophysiol 1987; 50: 344-346

3. Limousin P, Krack P, Pollak P, Benabid AL et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. New Engl J Med 1998; 339: 1105-1111

4. Molinuevo JL, Valldeoriola F, Tolosa E et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson's disease. Arch Neurol 2000; 57: 983-988

5. Pollak P, Fraix V, Krack P, Benabid AL et al. Treatment Results: Parkinson's disease. Mov Disord 2002; 17: S75-S83

6. Volkmann J, Allert N, Vogels J et al. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001; 56: 548-551

7. Martínez-Martín P, Valldeoriola F, Tolosa E et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord 2002; 17: 372-377

8. Tavella A, Bergamasco B, Bosticco E et al. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow up. Neurol Sci2002; 23: S111-S112

9. Moro E, Esselink RJA, Benabid AL et al. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 2002; 125: 2408-2417